Replimune And Incyte Enter Into Clinical Trial Collaboration And Supply Agreement To Evaluate RP1 And INCB99280 In Patients With Cutaneous Squamous Cell Carcinoma
Portfolio Pulse from Happy Mohamed
Replimune Group, Inc. (REPL) and Incyte (INCY) have announced a clinical trial collaboration and supply agreement to study RP1, Replimune's lead product candidate, in combination with INCB99280, Incyte's small molecule oral PD-L1 inhibitor. The trial, expected to initiate in early 2024, will focus on patients with high risk, resectable cutaneous squamous cell carcinoma (CSCC). Both companies will share equally in the costs of the study.
July 31, 2023 | 8:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Incyte's collaboration with Replimune to study the combination of RP1 and INCB99280 could potentially enhance the company's product portfolio and future revenues if the trial is successful.
The collaboration with Replimune could potentially enhance Incyte's product portfolio and future revenues if the trial is successful. This could lead to a positive impact on the company's stock in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Replimune's collaboration with Incyte to study the combination of RP1 and INCB99280 could potentially enhance the company's product portfolio and future revenues if the trial is successful.
The collaboration with Incyte could potentially enhance Replimune's product portfolio and future revenues if the trial is successful. This could lead to a positive impact on the company's stock in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100